Pacira Biosciences Inc
NASDAQ:PCRX

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
NASDAQ:PCRX
Watchlist
Price: 25.24 USD -2.21%
Market Cap: 1.2B USD

Intrinsic Value

The intrinsic value of one PCRX stock under the Base Case scenario is 61.94 USD. Compared to the current market price of 25.24 USD, Pacira Biosciences Inc is Undervalued by 59%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PCRX Intrinsic Value
61.94 USD
Undervaluation 59%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Pacira Biosciences Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
PCRX
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for PCRX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Pacira Biosciences Inc
NASDAQ:PCRX
US
Pharmaceuticals
Market Cap
1.2B USD
IPO
Feb 3, 2011
US
Pharmaceuticals
Market Cap
1.2B USD
IPO
Feb 3, 2011
Price
$false
EPS
$false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Pacira Biosciences Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pacira Biosciences Inc

Current Assets 745.1m
Cash & Short-Term Investments 484.6m
Receivables 113.3m
Other Current Assets 147.2m
Non-Current Assets 808.4m
Long-Term Investments 35.6m
PP&E 216.4m
Intangibles 426m
Other Non-Current Assets 130.4m
Efficiency

Free Cash Flow Analysis
Pacira Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Pacira Biosciences Inc

Revenue
701m USD
Cost of Revenue
-170.4m USD
Gross Profit
530.5m USD
Operating Expenses
-433m USD
Operating Income
97.6m USD
Other Expenses
-197.1m USD
Net Income
-99.6m USD
Fundamental Scores

PCRX Profitability Score
Profitability Due Diligence

Pacira Biosciences Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
52/100
Profitability
Score

Pacira Biosciences Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

PCRX Solvency Score
Solvency Due Diligence

Pacira Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
50/100
Solvency
Score

Pacira Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PCRX Price Targets Summary
Pacira Biosciences Inc

Wall Street analysts forecast PCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PCRX is 39.78 USD with a low forecast of 26.26 USD and a high forecast of 68.25 USD.

Lowest
Price Target
26.26 USD
4% Upside
Average
Price Target
39.78 USD
58% Upside
Highest
Price Target
68.25 USD
170% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Pacira Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PCRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PCRX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one PCRX stock?

The intrinsic value of one PCRX stock under the Base Case scenario is 61.94 USD.

Is PCRX stock undervalued or overvalued?

Compared to the current market price of 25.24 USD, Pacira Biosciences Inc is Undervalued by 59%.

Back to Top